Regulation, Reimbursement Notes From Turkey

A PharmAsia News update shows Turkey has set a target to domestically manufacture 60% of the drug products used annually and 20% of medical device and equipment by an unspecified timeframe. The government also moved to offer more support into R&D for high-value biopharmaceutical products and sent a large ministerial delegation to the annual Bio Conference in San Diego as a signal of how important the sector is to its public health programs.

ISTANBUL – Turkey’s government has moved anew to kick start domestic manufacture of drugs and medical equipment as costs and shortages loom despite efforts to curb spending and reform the reimbursement process partly in response to a push by local generic makers for more clarity ([A#28140504002]).

The effort coincides with government plans to boost R&D spending across the biomedical community and as the government once again...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Drug Pricing

Stock Watch: J&J’s $5bn Product Predictions Meet Investor Skepticism

 
• By 

Despite announcing sales growth that is currently weathering the storm of one of its biggest losses of exclusivity and a spin-off of its orthopedic division, J&J’s stock price weakened after its earnings announcement. Investors probably wanted more visibility on MFN.

Big Patent Blow For Roche’s Evrysdi In India But It May Not Be Over Yet

 

Roche, which faced a high stakes patent setback for Evrysdi in India, appears to have appealed against a lower court’s ruling, which went decisively Natco’s way but also included distinct 'reservations' by the judges.

US FDA Commissioner’s Involvement In AstraZeneca Pricing Deal Raises Ethical, Legal Questions

 

Marty Makary's role in helping negotiation the Trump Administration's second "most favored nations" drug pricing deal is raising concerns as the Trump team has suggested it would use drug pricing as a lever to impact FDA approval status or speed of drug reviews.

‘Building The Plane While Flying It’: Cell And Gene Therapy Makers Prepare For MFN Pricing, Tariffs

 
• By 

It remains to be seen whether the Trump administration’s most favored nation drug pricing policy will trickle down from big pharma to small biotech, but executives said at ARM’s Cell and Gene Meeting on the Mesa that they are preparing strategies now to manage the future.

More from Scrip

Sponsored by :

Podcast: Innovating Autoimmune Treatment with In Vivo CAR-T

As in vivo CAR-T therapy nears clinical use, researchers and industry leaders explore how it could transform autoimmune disease treatment. Novotech’s Pete Robinson joins Citeline’s Meredith Landry to discuss the science, strategy, and partnerships shaping the future of cell therapy.

How To Score A Win With Real-World Evidence In India

 
• By 

Bharat Serums showed it’s possible to score a regulatory win with real-world evidence (RWE) studies in India when it ran one leading to a label expansion for its mAb trinbelimab. As cell and gene therapies and rare disease drugs gain currency, sponsors could look at takeaways from the RhYTHM study.

Failing to Clinch Sale, Galapagos To Wind Down Cell Therapy Business

 
• By 

Galapagos is closing its cell therapy business after a prolonged search for buyers, leading to job cuts and site closures in the US, Netherlands, Switzerland and China.